Download PDF

1. Company Snapshot

1.a. Company Description

AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries.The company operates in two segments, Labtech and Medtech.The Labtech segment offers products, solutions, and services in the areas of diagnostics, and biomedical research and laboratory equipment for haematology, pathology, point-of-care diagnostics, cell biology, genetics, microbiology, virology, molecular biology, clinical chemistry, immunology, consumables, and analytical instruments segments.


This segment also offers support, maintenance, advice, and training services.The Medtech segment provides medical device products for surgery, respiration, intensive care, wound care, enteral nutrition, fall prevention, welfare technology, ear, and nose and throat segments, as well as bathroom-related assistive devices and assistive devices for children with disabilities.It operates in Sweden, Finland, Denmark, Norway, the United Kingdom, Ireland, Germany, Italy, Austria, Switzerland, rest of Europe, and internationally.


AddLife AB (publ) was founded in 1906 and is based in Stockholm, Sweden.

Show Full description

1.b. Last Insights on ALIF

AddLife AB's recent performance was driven by its strong Q4 2024 earnings, which showcased robust sales growth and significant financial improvements. The company's strategic advancements, such as its focus on expanding its product offerings, have positioned it for future growth despite some challenges. Notably, AddLife AB's management has demonstrated confidence in its growth prospects, as evidenced by the company's strong financial performance and strategic initiatives. Additionally, insider buying activity has been observed in the company, signaling confidence in its potential growth prospects.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

AddLife AB (LTS:0REZ) Q3 2025 Earnings Call Highlights: Robust Growth and Strategic ...

Nov -05

Source:

Card image cap

European Equities Estimated Below Intrinsic Value In August 2025

Aug -20

Source:

Card image cap

AddLife AB (FRA:1AD1) Q2 2025 Earnings Call Highlights: Strong Profit Growth Amid Acquisition Costs

Jul -16

Source:

Card image cap

3 European Stocks Estimated To Be Trading At Discounts Up To 39.4%

Jun -04

Source:

Card image cap

AddLife AB (FRA:1AD1) Q1 2025 Earnings Call Highlights: Strong Margin Improvements and ...

Apr -27

Source:

Card image cap

3 European Stocks Estimated To Be Trading Below Their Intrinsic Value In April 2025

Apr -18

Source:

Card image cap

3 European Stocks That May Be Undervalued By As Much As 39.6%

Mar -20

Source:

Card image cap

AddLife AB (FRA:1AD1) (Q4 2024) Earnings Call Highlights: Strong Finish with Robust Sales and ...

Feb -12

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (6.24%)

6. Segments

MedTech

Expected Growth: 7%

MedTech from AddLife AB (publ) achieves 7% growth driven by increasing demand for innovative medical devices, strategic acquisitions, and expansion into new markets. Additionally, investments in R&D, digitalization, and regulatory compliance contribute to the segment's growth. Furthermore, the aging population and rising healthcare expenditure also fuel the demand for MedTech products and services.

LabTech

Expected Growth: 5%

LabTech's 5% growth is driven by increasing demand for laboratory equipment and services, expansion into new markets, and strategic acquisitions. Additionally, investments in R&D and digitalization enable the company to stay competitive, while a strong sales network and customer relationships contribute to steady revenue growth.

Group Items

Expected Growth: 4%

AddLife AB's 4% growth is driven by increasing demand for healthcare technology and services, expansion into new markets, strategic acquisitions, and a strong focus on innovation and R&D. Additionally, the company's diversified portfolio and cost-effective solutions contribute to its growth momentum.

7. Detailed Products

Lab Equipment

AddLife AB provides a range of laboratory equipment, including microscopes, spectrophotometers, and centrifuges, designed to support life science research and development.

Molecular Diagnostics

AddLife offers molecular diagnostic solutions, including PCR instruments and reagents, for the detection and analysis of genetic material.

Bioprocessing

AddLife provides bioprocessing solutions, including bioreactors and fermentation systems, for the development and production of biopharmaceuticals.

Medical Imaging

AddLife offers medical imaging solutions, including MRI and CT scanners, for diagnostic and research applications.

In Vitro Diagnostics

AddLife provides in vitro diagnostic solutions, including immunoassay systems and reagents, for the detection and monitoring of diseases.

8. AddLife AB (publ)'s Porter Forces

Forces Ranking

Threat Of Substitutes

AddLife AB (publ) operates in the life science industry, which is characterized by a moderate threat of substitutes. While there are some alternative products and services available, they are not perfect substitutes, and the company's products and services have a unique value proposition.

Bargaining Power Of Customers

AddLife AB (publ) has a diverse customer base, and no single customer accounts for a significant portion of its revenue. This reduces the bargaining power of customers, as they do not have significant negotiating power.

Bargaining Power Of Suppliers

AddLife AB (publ) has a moderate dependence on its suppliers, particularly for raw materials and equipment. While the company has some negotiating power, suppliers also have some bargaining power due to the specialized nature of the products and services.

Threat Of New Entrants

The life science industry has high barriers to entry, including significant capital requirements, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market, reducing the threat of new entrants.

Intensity Of Rivalry

The life science industry is highly competitive, with many established players competing for market share. AddLife AB (publ) faces intense competition from other companies, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 49.92%
Debt Cost 9.21%
Equity Weight 50.08%
Equity Cost 10.13%
WACC 9.67%
Leverage 99.68%

11. Quality Control: AddLife AB (publ) passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Coltene

A-Score: 4.7/10

Value: 3.9

Growth: 2.7

Quality: 5.6

Yield: 8.1

Momentum: 2.0

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Safilo

A-Score: 4.6/10

Value: 6.9

Growth: 3.7

Quality: 6.3

Yield: 0.0

Momentum: 8.5

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Advanced Medical Solutions

A-Score: 3.8/10

Value: 3.0

Growth: 3.9

Quality: 5.2

Yield: 1.2

Momentum: 6.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
SKAN

A-Score: 3.6/10

Value: 0.6

Growth: 7.8

Quality: 5.8

Yield: 0.6

Momentum: 1.0

Volatility: 6.0

1-Year Total Return ->

View Full Report
Stock-Card
AddLife

A-Score: 3.6/10

Value: 1.5

Growth: 6.3

Quality: 4.1

Yield: 0.0

Momentum: 5.5

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Tobii Dynavox

A-Score: 2.6/10

Value: 0.2

Growth: 5.2

Quality: 4.2

Yield: 0.0

Momentum: 4.0

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

179.7$

Current Price

179.7$

Potential

-0.00%

Expected Cash-Flows